IVIG Does Not Exacerbate Gastroparesis—It May Improve Symptoms in Select Autoimmune Cases
IVIG is not known to worsen gastroparesis symptoms; in fact, emerging evidence suggests it may improve symptoms in patients with autoimmune gastroparesis (AGID), particularly those with positive glutamic acid decarboxylase (GAD) antibodies. 1, 2
Evidence for IVIG as Treatment (Not Exacerbation)
The available literature exclusively describes IVIG as a therapeutic intervention for refractory gastroparesis, not as a causative or exacerbating agent:
Clinical Response Data
In a 2025 retrospective series of 24 AGID patients treated with IVIG, mean Gastroparesis Cardinal Symptom Index (GCSI) scores improved by over 1.5 points (pre-IVIG: 3.64, post-IVIG: 2.01, p<0.001), with 67% achieving ≥1 point improvement. 1
GAD-positive patients (41.7% of cohort) demonstrated the most significant symptom improvement, with a mean GCSI reduction of -2.3 points compared to -1.1 in GAD-negative patients (p=0.02). 1
A 2023 study of 47 drug- and device-refractory gastroparesis patients treated with standardized 12-week IVIG (400 mg/kg weekly) showed 30% response rate, defined as ≥20% reduction in symptom scores. 2
Responders had higher GAD65 positivity (64% vs. 30%, p=0.049) and longer duration of therapy (>12 weeks: 86% vs. 48%, p=0.09). 2
Mechanism and Patient Selection
IVIG targets neuroinflammation in patients with autoimmune dysautonomia presenting with gastroparesis, particularly those with positive GAD65 autoantibodies and evidence of neuroinflammation on full-thickness gastric biopsy. 3
Maximum symptom improvement (67%) was observed with IVIG therapy, with 55% of patients showing improvement in vomiting and 45% improving in nausea, abdominal pain, and bloating. 3
FDA-Labeled Adverse Effects of IVIG (None Gastroparesis-Related)
The FDA labeling for IVIG products lists multiple adverse effects, but gastrointestinal symptoms or gastroparesis exacerbation are not among them: 4
- Hypersensitivity reactions and anaphylaxis (particularly in IgA-deficient patients with anti-IgA antibodies) 4
- Renal dysfunction/failure (especially with sucrose-containing formulations) 4
- Thrombosis (risk factors include advanced age, immobilization, hypercoagulability, cardiovascular disease) 4
- Aseptic meningitis syndrome (onset within hours to 2 days post-infusion) 4
- Hemolysis (particularly after high-dose therapy) 4
- Transfusion-related acute lung injury (TRALI) 4
Important Caveats
Hyperproteinemia and increased serum viscosity may occur with IVIG, potentially leading to pseudohyponatremia and volume depletion if mismanaged, which could theoretically worsen any underlying condition through dehydration. 4
However, this is a general metabolic effect, not a direct gastrointestinal or gastroparesis-specific complication.
Clinical Context: When to Consider IVIG
IVIG should be reserved for severely refractory gastroparesis patients who have failed standard therapies (metoclopramide, dietary modifications, antiemetics) and have evidence of autoimmune dysfunction. 5, 1, 2
Diagnostic Workup Before IVIG
Obtain serum autoantibodies including GAD65, neuronal voltage-gated calcium channel, acetylcholine receptor, and neuronal voltage-gated potassium channel antibodies. 1
Consider full-thickness gastric biopsy to evaluate for neuroinflammation in select cases. 3
Confirm delayed gastric emptying with 4-hour gastric emptying scintigraphy (not 2-hour testing). 6
Treatment Protocol
Standard IVIG dosing for AGID is 400 mg/kg weekly for a minimum of 12 weeks, with consideration for extended therapy (>12 weeks) in responders. 2, 3
Monitor for FDA-labeled adverse effects: baseline renal function (BUN, creatinine), blood viscosity assessment in high-risk patients, and adequate hydration before each infusion. 4
Bottom Line
There is no evidence that IVIG exacerbates gastroparesis symptoms. The entire body of literature positions IVIG as a potential therapeutic option for autoimmune gastroparesis, with the strongest benefit seen in GAD-positive patients who have exhausted conventional therapies. 1, 2, 3 If a patient develops worsening gastrointestinal symptoms temporally related to IVIG, consider alternative explanations such as volume depletion from hyperproteinemia, concurrent infections, or progression of underlying disease rather than direct IVIG-induced gastroparesis exacerbation.